Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Rating of “Reduce” by Analysts

Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI) have been given an average rating of “Reduce” by the seven analysts that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $4.77.

A number of research analysts recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Treace Medical Concepts in a research report on Monday, April 20th. Lake Street Capital decreased their target price on shares of Treace Medical Concepts from $7.50 to $7.00 and set a “buy” rating for the company in a research note on Monday, March 2nd. Finally, Wall Street Zen raised Treace Medical Concepts from a “strong sell” rating to a “sell” rating in a report on Monday, April 27th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Graham Capital Management L.P. bought a new stake in shares of Treace Medical Concepts during the 4th quarter valued at about $27,000. Osaic Holdings Inc. lifted its stake in shares of Treace Medical Concepts by 328.3% in the 2nd quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock worth $28,000 after purchasing an additional 3,674 shares during the period. HighTower Advisors LLC bought a new position in shares of Treace Medical Concepts in the 4th quarter worth approximately $33,000. Chicago Partners Investment Group LLC boosted its holdings in shares of Treace Medical Concepts by 34.0% in the first quarter. Chicago Partners Investment Group LLC now owns 26,014 shares of the company’s stock worth $35,000 after buying an additional 6,606 shares during the last quarter. Finally, Balance Wealth LLC purchased a new position in shares of Treace Medical Concepts in the fourth quarter worth approximately $37,000. Institutional investors own 84.08% of the company’s stock.

Treace Medical Concepts Price Performance

NASDAQ TMCI opened at $1.92 on Friday. Treace Medical Concepts has a one year low of $1.17 and a one year high of $7.78. The stock has a 50-day moving average of $1.62 and a 200 day moving average of $2.65. The company has a market capitalization of $124.38 million, a price-to-earnings ratio of -2.04 and a beta of 1.10. The company has a debt-to-equity ratio of 0.64, a quick ratio of 3.13 and a current ratio of 4.31.

Treace Medical Concepts (NASDAQ:TMCI) last posted its earnings results on Friday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.15). Treace Medical Concepts had a negative net margin of 27.74% and a negative return on equity of 59.91%. The business had revenue of $62.52 million for the quarter, compared to analysts’ expectations of $61.76 million. On average, sell-side analysts forecast that Treace Medical Concepts will post -0.92 EPS for the current year.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.